long-term survival of a patient with pancreatic cancer with metastases
to the liver after treatment with the intravenous alpha-lipoic
acid/low-dose naltrexone protocol.
Berkson BM, Rubin DM, Berkson AJ.Integrative Medical Center of New Mexico and New Mexico State University, Las Cruces.The
authors describe the long-term survival of a patient with pancreatic
cancer without any toxic adverse effects. The treatment regimen
includes the intravenous alpha-lipoic acid and low-dose naltrexone
(ALA-N) protocol and a healthy lifestyle program. The patient was told
by a reputable university oncology center in October 2002 that there
was little hope for his survival. Today, January 2006, however, he is
back at work, free from symptoms, and without appreciable progression
of his malignancy. The integrative protocol described in this article
may have the possibility of extending the life of a patient who would
be customarily considered to be terminal. The authors believe that life
scientists will one day develop a cure for metastatic pancreatic
cancer, perhaps via gene therapy or another biological platform. But
until such protocols come to market, the ALA-N protocol should be
studied and considered, given its lack of toxicity at levels reported.
Several other patients are on this treatment protocol and appear to be
doing well at this time.Integr Cancer Ther. 2006 Mar;5(1):83-9.
The long-term survival of a patient with pancreatic cancer with metastases to the liver after treatment with the intravenous alp